MedTrace Logo

Doses of Coffee and Blood Pressure Response Post-exercise

NCT02335840 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-01-12

No results posted yet for this study

Summary

Introduction: reduction of blood pressure after physical exercise is called post exercise hypotension (PEH). However, previous studies demonstrate that ingestion of caffeine equivalent to three tea-cup of coffee abolishes this phenomenon. Objective: evaluate the influence of different doses of coffee in PEH. Methods: eleven hypertensive performed four experimental sessions of aerobic exercise in cycle ergometer (40 minutes of duration, intensity between 60% and 80% of maximum heart rate) succeeds for the ingestion of one (CAF-1), two (CAF-2), three (CAF-3) doses of caffeinated coffee (144 mg/dose), or three doses of decaffeinated coffee (DESC). Blood pressure was measured in rest and during 120 minutes of recovery post exercise, each 10 minutes.

Conditions

Interventions

OTHER

CAF-1

In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine

OTHER

CAF-2

In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine

OTHER

CAF-3

In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine

OTHER

DESC

In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine

Sponsors & Collaborators

  • Federal University of Paraíba

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-05-31
Completion
2014-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02335840 on ClinicalTrials.gov